Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates stable financial performance with moderate growth in contract sales. The Q&A reveals confidence in KIMMTRAK's market position, but management's vague responses on key metrics and competition introduce uncertainty. The lack of new partnerships or guidance changes suggests limited short-term catalysts. Given the small-cap status, the stock may experience slight volatility, but overall, the sentiment remains neutral.
Key Financial Performance
Net Revenue from KIMMTRAK $400 million, up over 29% from the prior year. Growth driven by deeper U.S. community penetration and continued global expansion.
Real-world duration of therapy for KIMMTRAK 14 months, exceeding clinical trials experience. This improvement reflects the transformative impact of KIMMTRAK on patient survival.
Balance Sheet Cash Approximately $864 million in cash, an increase of more than $40 million versus last year. This increase provides flexibility to advance the pipeline.
SG&A Expenses Marginally higher versus 2024. Increase attributed to disciplined spending and commercial preparations for potential expansion of KIMMTRAK into cutaneous melanoma.
R&D Expenses Increased in 2025 due to ongoing investments in three Phase III trials and earlier-stage programs. Expected to increase modestly in 2026, but at a slower rate than in 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
KIMMTRAK net revenue: Generated $400 million in 2025, a 29% increase from the prior year.
KIMMTRAK approvals and launches: Approved in 39 countries and launched in 30 markets.
KIMMTRAK therapy duration: Real-world duration of therapy is now 14 months, exceeding clinical trials.
KIMMTRAK life cycle management: Two Phase III trials: TEBE-AM in second-line cutaneous melanoma and ATOM in adjuvant uveal melanoma.
New Phase III trial: PRISM-MEL-301 with brenetafusp in first-line cutaneous melanoma.
Global expansion: KIMMTRAK achieved 70% penetration in major markets and activated 150 new accounts in 2025.
Community adoption: 70% of prescriptions and half of patient starts are from the community setting.
Pipeline diversification: Expanding oncology platform into ovarian, lung, colorectal, and GI cancers.
Infectious disease programs: Promising data for HIV functional cure and hepatitis B candidate.
Autoimmune disease program: Submitted CTA for Type 1 diabetes program, with Phase I trials expected in 2026.
Financial strength: $864 million in cash, providing flexibility for pipeline advancement.
R&D investment: Focused on three Phase III trials and early-stage programs.
Commercial preparations: Incremental SG&A investments for potential KIMMTRAK expansion into cutaneous melanoma.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Growth Moderation: As KIMMTRAK enters its fifth year on the market, growth is expected to moderate due to significant penetration across all major markets, potentially impacting revenue growth.
Regulatory and Clinical Trial Risks: The success of ongoing Phase III trials (TEBE-AM, ATOM, PRISM-MEL-301) is critical for future growth. Delays or negative outcomes in these trials could hinder expansion into new indications and markets.
Competitive Pressures: Emerging therapies in melanoma and other oncology areas could challenge KIMMTRAK's market position, especially in the cutaneous melanoma and uveal melanoma settings.
Supply Chain and Operational Risks: Expanding global reach and activating new clinical trial sites, particularly in the U.S. and Europe, may face logistical and operational challenges.
Economic Uncertainties: Global economic conditions could impact healthcare budgets and patient access to therapies, potentially affecting sales and market expansion.
Pipeline Diversification Challenges: Efforts to expand into infectious diseases and autoimmune conditions are in early stages, and success is uncertain. Failure in these areas could limit long-term growth opportunities.
R&D Investment Pressures: Increased R&D expenses for advancing Phase III trials and early-stage programs could strain financial resources if revenue growth slows.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
KIMMTRAK Revenue Growth: KIMMTRAK generated $400 million in net revenue in 2025, marking a 29% year-over-year growth. However, growth is expected to moderate in 2026 as the product enters its fifth year on the market.
Phase III Trials for KIMMTRAK: Two Phase III trials are underway: TEBE-AM in second-line cutaneous melanoma, with enrollment completion expected in the first half of 2026, and ATOM in adjuvant uveal melanoma, with U.S. site activations planned for the first half of 2026.
PRISM-MEL-301 Trial: A third Phase III trial, PRISM-MEL-301, is ongoing for brenetafusp in first-line cutaneous melanoma. Enrollment completion is targeted for 2027.
Pipeline Expansion Beyond Melanoma: The oncology platform is expanding into ovarian, lung, colorectal, and GI cancers. Data from ovarian and lung cancer cohorts are expected in the second half of 2026.
HIV Functional Cure Program: The HIV program is progressing with dose escalation studies, and data is expected in the second half of 2026.
Type 1 Diabetes Program: The first patient in the Type 1 diabetes Phase I trial is expected to be dosed in the first half of 2026.
Financial Guidance for 2026: R&D expenses are expected to increase modestly in 2026, driven by ongoing Phase III trials and early-stage programs. SG&A expenses will see incremental increases for commercial preparations for KIMMTRAK's potential expansion into cutaneous melanoma.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you remind me the general geographic breakdown of your enrollment for TEBE-AM?
A:The majority of enrollment is coming from Europe, with 10-15% from the U.S. and the rest from other countries.
Q:Did you go through a DSMB analysis or a look to test that KIMMTRAK alone is probably doing at least as good as the combo?
A:The original TEBE design was a Phase II/III design, later converted into a Phase III seamless trial based on enrollment metrics. Neither the data nor the IDMC was reviewed, saving 1 year in trial conduct.
Q:What are both treatment arms powered for on overall survival in TEBE-AM?
A:The study is designed to meet both statistically significant and clinically meaningful thresholds, with at least a 30% difference from the control. The combo may outperform the mono based on prior data.
Q:Do you have a value in mind for contract sales growth that is substantially less than 25%?
A:Growth is expected to moderate from 25% to around 20% after normalizing for rebate reserves. Quarterly growth rates are expected to decline from 4-7%.
Q:Is cash flow breakeven in 2025 a reasonable estimate for 2026?
A:R&D expenses are expected to modestly increase into 2026, while SG&A expenses will see only incremental increases. Cash flow breakeven remains a focus.
Q:How does the team think about pricing in the second-line cutaneous melanoma market?
A:Pricing will depend on the unmet need, overall survival endpoint, established safety, and off-the-shelf treatment benefits. The team believes they can defend the price appropriately if the data is positive.
Q:How do you evaluate success in early autoimmune studies relative to oncology benchmarks?
A:Type 1 diabetes was chosen to determine early success by measuring drug binding to the target and using C-peptide as a surrogate for efficacy before engaging in larger Phase IIb studies.
Q:How could the learnings from KIMMTRAK in uveal melanoma apply to a potential commercial launch in cutaneous melanoma?
A:Half of cutaneous melanoma patients are treated by physicians experienced with KIMMTRAK. The team is well-trained and has a track record of successful launches, providing a strong foundation for a potential launch.
Q:What are the different scenarios for the PRAME portfolio data update in the second half?
A:The company will evaluate the totality of data from several hundred patients and ongoing trials to guide next steps. This provides optionality for advancing one or more assets.
Q:What are the expectations for the HIV program update later this year?
A:The update will include data from small Phase I dose-escalation cohorts, aiming to identify the right dose and assess the impact on the viral reservoir and viral rebound.
Q:How are you thinking about the upcoming competitor readout in frontline uveal from IDEYA?
A:The team will look for randomized Phase III data, focusing on hazard ratio and safety. They remain confident in KIMMTRAK's robust data and real-world evidence.
Q:Can you lay out the percentage mix in the control arm for TEBE-AM?
A:About 1/3 of control arm patients will likely be retreated with checkpoint inhibitors, others with BRAF-based regimens, chemotherapy, or clinical trials. TILs are not approved in Europe, where most patients are enrolled.
Q:How do you view the evolving landscape for second-line cutaneous melanoma and KIMMTRAK's role?
A:KIMMTRAK has an OS endpoint, long-term safety, and is off-the-shelf. It is expected to have a significant advantage over selective therapies like TILs and TCR-T.
Q:What do you need to see in the upcoming ovarian and lung readouts to move forward in development?
A:The company is looking for safety and early signals in maintenance settings for ovarian cancer and signal searching in lung cancer. The totality of data will guide next steps.
Q:What should we look for in the half-life extended PRAME data?
A:The focus is on convenience and potential improvements in ORR. The data will determine whether to advance PRAME HLE or brenetafusp.
Q:What was the assumed median OS in the control arm for TEBE-AM, and has it changed?
A:The assumed median OS in the control arm is 12-13 months with a 1-year survival rate of 55%. These assumptions have not changed.
Q:What are the event assumptions driving the timing of TEBE-AM data?
A:The data is event-driven with an OS endpoint. The trial is expected to report results as early as the second half of 2026, depending on event occurrences.
Q:Review of Unclear Management Responses
A:Management avoided providing specific statistical assumptions for treatment arms in TEBE-AM and did not detail the exact efficacy benchmarks for early autoimmune studies. They also used vague language when discussing the potential impact of competitor readouts and the evolving landscape for second-line cutaneous melanoma.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATOM melanoma
CROI
Chief Medical
Development
Dr Jallal
Executive VP
IDMC
Immunocore
KIMMTRAK result
Medical Officer
RD engine
Today
Type diabetes
adoption KIMMTRAK
afternoon
beta cell
brenetafusp
candidate SAI
cell pancreas
combination chemotherapy
completion
diabetes program
enrollment
evidence
flexibility
investment
life cycle
lung cancer
melanoma setting
microgram dose
opportunity melanoma
patient year
preparation
setting line
site
survival endpoint
therapy survival
world
IMCR Transcript
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call summary indicates stable financial performance with moderate growth in contract sales. The Q&A reveals confidence in KIMMTRAK's market position, but management's vague responses on key metrics and competition introduce uncertainty. The lack of new partnerships or guidance changes suggests limited short-term catalysts. Given the small-cap status, the stock may experience slight volatility, but overall, the sentiment remains neutral.
NorthWest Healthcare Properties Real Estate Investment Trust (NWH.UN:CA) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call highlights a mixed outlook. Positive factors include strategic focus on outpatient assets, significant opportunity in Canada, and plans to reduce debt. However, the European asset sale did not meet pricing expectations, and there's no clear guidance on FFO per share. The company is undergoing a transformation, but uncertainties remain, such as unclear management responses and potential dilution from equity raises. Given the market cap of approximately $1.7 billion, these mixed signals suggest a neutral stock price movement in the short term.
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
IMCR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
